F2R and myocardial infarction: PAR-1 antagonists are a recently discovered class of antiplatelet drugs, among which vorapaxar selectively inhibits thrombin-induced platelet aggregation and it is used for the treatment of patients who have suffered a myocardial infarction (heart attack) or peripheral arterial disease [88].